RATIONALE: Donor mesenchymal stromal/stem cell (MSC) expansion and fibrotic differentiation is associated with development of bronchiolitis obliterans syndrome (BOS) in human lung allografts. However, the regulators of fibrotic differentiation of these resident mesenchymal cells are not well understood. OBJECTIVES: This study examines the role of endogenous and exogenous prostaglandin (PG)E2 as a modulator of fibrotic differentiation of human lung allograft-derived MSCs. METHODS: Effect of PGE2 on proliferation, collagen secretion, and α-smooth muscle actin (α-SMA) expression was assessed in lung-resident MSCs (LR-MSCs) derived from patients with and without BOS. The response pathway involved was elucidated by use of specific agonists and antagonists. MEASUREMENT AND MAIN RESULTS: PGE2 treatment of LR-MSCs derived from normal lung allografts significantly inhibited their proliferation, collagen secretion, and α-SMA expression. On the basis of pharmacologic and small-interfering RNA approaches, a PGE2/E prostanoid (EP)2/adenylate cyclase pathway was implicated in these suppressive effects. Stimulation of endogenous PGE2 secretion by IL-1β was associated with amelioration of their myofibroblast differentiation in vitro, whereas its inhibition by indomethacin augmented α-SMA expression. LR-MSCs from patients with BOS secreted significantly less PGE2 than non-BOS LR-MSCs. Furthermore, BOS LR-MSCs were found to be defective in their ability to induce cyclooxygenase-2, and therefore unable to up-regulate PGE2 synthesis in response to IL-1β. BOS LR-MSCs also demonstrated resistance to the inhibitory actions of PGE2 in association with a reduction in the EP2/EP1 ratio. CONCLUSIONS: These data identify the PGE2 axis as an important autocrine-paracrine brake on fibrotic differentiation of LR-MSCs, a failure of which is associated with BOS.
RATIONALE: Donor mesenchymal stromal/stem cell (MSC) expansion and fibrotic differentiation is associated with development of bronchiolitis obliterans syndrome (BOS) in human lung allografts. However, the regulators of fibrotic differentiation of these resident mesenchymal cells are not well understood. OBJECTIVES: This study examines the role of endogenous and exogenous prostaglandin (PG)E2 as a modulator of fibrotic differentiation of human lung allograft-derived MSCs. METHODS: Effect of PGE2 on proliferation, collagen secretion, and α-smooth muscle actin (α-SMA) expression was assessed in lung-resident MSCs (LR-MSCs) derived from patients with and without BOS. The response pathway involved was elucidated by use of specific agonists and antagonists. MEASUREMENT AND MAIN RESULTS:PGE2 treatment of LR-MSCs derived from normal lung allografts significantly inhibited their proliferation, collagen secretion, and α-SMA expression. On the basis of pharmacologic and small-interfering RNA approaches, a PGE2/E prostanoid (EP)2/adenylate cyclase pathway was implicated in these suppressive effects. Stimulation of endogenous PGE2 secretion by IL-1β was associated with amelioration of their myofibroblast differentiation in vitro, whereas its inhibition by indomethacin augmented α-SMA expression. LR-MSCs from patients with BOS secreted significantly less PGE2 than non-BOS LR-MSCs. Furthermore, BOS LR-MSCs were found to be defective in their ability to induce cyclooxygenase-2, and therefore unable to up-regulate PGE2 synthesis in response to IL-1β. BOS LR-MSCs also demonstrated resistance to the inhibitory actions of PGE2 in association with a reduction in the EP2/EP1 ratio. CONCLUSIONS: These data identify the PGE2 axis as an important autocrine-paracrine brake on fibrotic differentiation of LR-MSCs, a failure of which is associated with BOS.
Authors: N Geudens; B M Vanaudenaerde; A P Neyrinck; C Van De Wauwer; R Vos; G M Verleden; E Verbeken; T Lerut; D E M Van Raemdonck Journal: Transplant Proc Date: 2007-10 Impact factor: 1.066
Authors: Lamis Jarvinen; Linda Badri; Scott Wettlaufer; Takashi Ohtsuka; Theodore J Standiford; Galen B Toews; David J Pinsky; Marc Peters-Golden; Vibha N Lama Journal: J Immunol Date: 2008-09-15 Impact factor: 5.422
Authors: Steven K Huang; Scott H Wettlaufer; Cory M Hogaboam; Kevin R Flaherty; Fernando J Martinez; Jeffrey L Myers; Thomas V Colby; William D Travis; Galen B Toews; Marc Peters-Golden Journal: Am J Respir Crit Care Med Date: 2007-10-04 Impact factor: 21.405
Authors: L Valfrè di Bonzo; I Ferrero; C Cravanzola; K Mareschi; D Rustichell; E Novo; F Sanavio; S Cannito; E Zamara; M Bertero; A Davit; S Francica; F Novelli; S Colombatto; F Fagioli; M Parola Journal: Gut Date: 2007-07-16 Impact factor: 23.059
Authors: Vibha N Lama; Susan Murray; Robert J Lonigro; Galen B Toews; Andrew Chang; Christine Lau; Andrew Flint; Kevin M Chan; Fernando J Martinez Journal: Am J Respir Crit Care Med Date: 2007-03-08 Impact factor: 21.405
Authors: Michael P Combs; Meng Xia; David S Wheeler; Elizabeth A Belloli; Natalie M Walker; Russell R Braeuer; Dennis M Lyu; Susan Murray; Vibha N Lama Journal: J Heart Lung Transplant Date: 2020-04-19 Impact factor: 10.247
Authors: Qiyuan Zhou; Tianji Chen; Wei Zhang; Melike Bozkanat; Yongchao Li; Lei Xiao; Richard B van Breemen; John W Christman; Jacob I Sznajder; Guofei Zhou Journal: Am J Respir Cell Mol Biol Date: 2016-05 Impact factor: 6.914
Authors: Shannon H Lacy; Amali P Epa; Stephen J Pollock; Collynn F Woeller; Thomas H Thatcher; Richard P Phipps; Patricia J Sime Journal: Am J Physiol Lung Cell Mol Physiol Date: 2017-12-20 Impact factor: 5.464